Last quarter (Q4 2022), Tryptamine Therapeutics's total revenue was $―, a decrease of ― from previous quarter. In Q4, Tryptamine Therapeutics's net income was $―. See Tryptamine Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19
Total Revenue	$ ―	$ 99.73K	$ ―	$ 2.62M	$ ―
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ 99.73K	$ ―	$ 2.62M	$ ―
Operating Expense	$ ―	$ 14.21M	$ 12.67M	$ 8.00M	$ 2.31M
Operating Income	$ ―	$ -14.11M	$ -12.67M	$ -8.00M	$ -2.31M
Net Non Operating Interest Income Expense	$ ―	$ -78.21K	$ 7.05K	$ 60.58K	$ 28.79K
Other Income Expense	$ ―	$ 4.11M	$ 4.19M	$ 2.67M	$ ―
Pretax Income	$ ―	$ -10.08M	$ -8.47M	$ -5.28M	$ -2.28M
Tax Provision	$ ―	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -10.08M	$ -8.47M	$ -5.28M	$ -2.28M
Basic EPS	$ ―	$ -0.06	$ -0.06	$ -0.06	$ ―
Diluted EPS	$ ―	$ -0.06	$ -0.06	$ -0.06	$ ―
Basic Average Shares	$ ―	$ 177.70M	$ 130.60M	$ 94.01M	$ ―
Diluted Average Shares	$ ―	$ 177.70M	$ 130.60M	$ 94.01M	$ ―
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income From Continuing And Discontinued Operation	$ ―	$ -10.08M	$ -8.47M	$ -5.28M	$ -2.28M
Normalized Income	$ ―	$ -10.08M	$ -8.47M	$ -5.28M	$ -2.28M
Interest Expense	$ ―	$ 81.22K	$ ―	$ ―	$ ―
EBIT	$ ―	$ -10.00M	$ -12.67M	$ -8.00M	$ -2.31M
EBITDA	$ ―	$ -8.27M	$ -11.66M	$ -7.62M	$ -2.31M

Currency in USD

Tryptamine Therapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing